Abstract
Interferon-alpha-2a is a recombinant interferon with antiviral, antitumour and immunomodulatory properties. Clinical studies have demonstrated that the drug offers therapeutic benefit in patients with some forms of chronic viral hepatitis. Remission, as measured by clearance of viral DNA and hepatitis B 'e' antigen (HBeAg), and normalisation of serum alanine aminotransferase levels, is observed in approximately 30 to 45% of patients with chronic hepatitis B receiving interferon-alpha-2a (2.5 to 18MU administered 3 times/week); about 5 to 15% of untreated controls remit spontaneously every year. Complete recovery [with loss of hepatitis B surface antigen (HBsAg)] is usually noted in < 20% of treated individuals. Similar response rates have been reported in the relatively small number of children evaluated to date. Although numerous studies have shown that interferon-alpha-2a (at various dosages) induces biochemical amelioration of chronic hepatitis C in approximately 50 to 75% of patients, relapse is common. Thus, long term remission may only be observed in about 15 to 30% of treated patients. On the other hand, this disorder remits spontaneously in only a few patients. The role of interferon-alpha-2a in the treatment of chronic...Continue Reading
Citations
Jun 1, 1997·Journal of the American Geriatrics Society·E L Marcus, R Tur-Kaspa
Jul 26, 2005·Phytotherapy Research : PTR·Dur Han KwonYong Kyung Choi
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·C AjariyakhajornD H Libraty
Jul 27, 2006·Basic & Clinical Pharmacology & Toxicology·Victor E BuckwoldPeter Langecker
Feb 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·J PetersenC E Rogler
Jun 1, 2002·Paediatric Drugs·Etienne Sokal
Mar 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J HoffF Raffi
Aug 20, 2005·Journal of Viral Hepatitis·A Kramvis, M C Kew
Oct 6, 2001·Journal of Clinical Gastroenterology·A F CelikG Ozbay
Jan 19, 2005·World Journal of Gastroenterology : WJG·Geng-Tao LiuLing-Zhi Wang
Apr 12, 2005·Drugs·Gayle W RobinsGillian M Keating
Jun 10, 2004·World Journal of Gastroenterology : WJG·Min Li, Geng-Tao Liu
Feb 24, 2007·International Ophthalmology·Valerie TouitouBahram Bodaghi
Nov 6, 2008·Expert Opinion on Drug Safety·Nikroo HashemiSteven K Herrine
Mar 16, 2004·Fundamental & Clinical Pharmacology·Necati Ormeci
May 3, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mark SulkowskiJian Yu
Apr 25, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Klaus LiebMartin Schaefer
Apr 14, 2012·Tropical Medicine and Health·Lyre Anni Espada-Murao, Kouichi Morita
Feb 21, 2021·Advanced Drug Delivery Reviews·Pyae PhyoYongchao Su
Mar 28, 2003·Journal of Pharmaceutical Sciences·Vikas K Sharma, Devendra S Kalonia
Dec 18, 2003·Clinics in Dermatology·Peggy LinStephen K Tyring